Company intelligence / Profile preview

Endacea, Inc.

Research Triangle Park/Durham area, North Carolina, United Statesendacea.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

The lead compound L‑97‑1, a water-soluble, orally bioavailable "best-in-class" A1 AR antagonist, has demonstrated proof-of-concept efficacy as an adjunctive anti-sepsis treatment in animal models of polymicrobial sepsis and endotoxemia. The company also develops a companion diagnostic endotoxin assay to identify patients at risk or suffering from sepsis. No clinical trial phases reported yet; development remains preclinical with strong focus on biodefense and inflammatory conditions[1][2][3][5].

Therapeutic areas: ImmunologyPulmonologyInfectious DiseasesNephrology
Modalities: Small molecule drugs (A1 adenosine receptor antagonists)Diagnostic assays (endotoxin assay for sepsis detection)
Industry: Biotech

Drug pipeline

1 asset

L-97-1

Preclinical

Beyond the preview

Go deeper on Endacea, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endacea, Inc..

Explore the full profile